Fig. 5.

(A) The strength of subject P2's T cell response to the HERV-K FAFTIPAI peptide decreased according to the peptide concentration in the ELISPOT assay well. (B) Subject P2's HIV-1 viral load and CD4⁺ T cell count over the course of 10 years. (C) This individual's response to HERV-K FI8, homologous HIV-1 peptide TI8, and an HIV-1 peptide pool waned just before the subject was put on HAART. In contrast, the CMV pp65 response was maintained over these time points. Note that the response to HIV-1 TAFTIPSI was not tested at the 2005 time point.